Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - First administration to humans
Status
Authorised, recruitment pending
Participants planned
25
Countries
1
Sites
1
Chronic allergic rhinitis
Key facts
- Sponsor
- Dianosic
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Respiratory Tract Diseases [C08]
- Decision date (initial)
- 2026-05-21
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Chronic allergic rhinitis
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Dianosic
- Sponsor organisation
- Dianosic
- Address
- Batiment Ph 8, 8 Place De L Hopital 8 Place De L Hopital
- City
- Strasbourg
- Postcode
- 67000
- Country
- France
Scientific contact point
- Organisation
- Dianosic
- Contact name
- Chief Scientific Officer
Public contact point
- Organisation
- Dianosic
- Contact name
- Chief Scientific Officer
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Netherlands | Authorised, recruitment pending | 25 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Amsterdam University Medical Center, VUmc Boelelaan
Ear, Nose and Throat (AMC), De Boelelaan 1117, 1081 HV, Amsterdam
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2026-02-10 | Netherlands | Acceptable 2026-05-20
|
2026-05-21 |